Skip to main content
Premium Trial:

Request an Annual Quote

Vision Medicals Gets CE Mark for SARS-CoV-2 Clinical Sequencing Test

NEW YORK – Vision Medicals has received the CE-IVD mark for its SARS-CoV-2 Clinical Sequencing assay, which uses next-generation sequencing.

The test is built on a proprietary metagenomic sequencing assay that runs on an Illumina NextSeq sequencer. Each kit contains 36 tests and is able to detect SARS-CoV-2 at a sensitivity of 500 copies per milliliter. With the CE mark in hand, Vision Medicals plans to focus on the European market.

The startup, based in Guangzhou, China, has been developing a CRISPR-based diagnostic test for tuberculosis.  Last September, the firm raised $14 million in a Series A financing round.

Vision Medicals also recently published a preprint on a CRISPR-based SARS-CoV-2 diagnostic test, named CRISPR-nCoV, which is different from its CE-marked test.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.